35 results about "Sucrose sulfate" patented technology

A pharmaceutical composition is described comprising sucralfate gel, PVA and optionally a vegetable product comprising tocotrienols and tocopherols. In particular, this composition proved to be suitable for being sprayed, and is advantageously used in the treatment of skin lesions, even deep lesions, such as second-degree burns.

The invention discloses a composite western medicine formula for treating gout. The composite western medicine is prepared from, by weight per granule, 0.2-0.5 g of sucralfate, 0.01-0.2 g of diclofenac sodium, 0.01-0.1 g of magnesium oxide, 0.1-0.3 g of benzbromarone and 0.2-1.5 g of chitin. According to the composite western medicine formula for treating the gout, the good gout treatment using effect is achieved; the activity of xanthine oxidase can be inhibited by using the benzbromarone, and therefore the concentration of uric acid in human blood is effectively lowered; by using the sucralfate, a layer of a protective film is formed to cover the ulcer surface, the effect of protecting the gastric mucosa is achieved, the using side effects of medicine on patients suffering from gastric ulcer and the like are effectively reduced, and meanwhile the effects of eliminating inflammation and relieving pain are obvious; by using the chitin, the effects of activating cells in a human body, preventing cell aging, promoting a newly-born cell band, adsorbing harmful heavy metal ions in the body, promoting human body detoxifying and the like can be achieved; gout patients can be effectively treated, and use is very convenient.

This invention is directed to new drug delivery systems (SMS packaging™) and uses thereof, of freshly prepared, effective, high concentrated, hygienic pharmaceutical compositions. The new delivery systems, including sucralfate, is used for treating and preventing oral diseases in mammals. Moreover this invention provides pharmaceutical compositions, methods and kits for topical administration to oral ulcers comprising sucralfate (Aftapet™ Aftakid™ Aftakit™ Chemokit™). This invention is a platform delivery system for any drug, which needs a fresh mixture of powder and water,

The present invention provides compositions and methods for the selective identification of damaged sites in the gastrointestinal tract. More particularly, the compositions comprise a phosphated and/or sulfated saccharide, such as sucralfate, containing one or more optical molecules.

Sucralfate gel in the dry state in porous granular form having a particle-size distribution of between 100 and 1000 mum, an apparent density of the powder bed of between 0.7 and 0.9 g/ml, a settling index of between 5 and 15%, and a residual humidity of between 5 and 15%, and the corresponding process of preparation, which comprises a treatment with microwaves of a diluted solution of powdered sucralfate gel, with a sucralfate titre of between 20 and 70 wt. %. This solid product may be advantageously used in the preparation of solid pharmaceutical compositions that contain it as single active principle, or else as coating of solid compositions that contain, as active principle, a substance that may cause lesions to the gastric mucosa.

The invention relates to a formula of a western medicine for treating ulcer and a preparation process for the western medicine. The western medicine is prepared from the following raw materials in parts by weight: 18-22 parts of aluminium hydroxide, 10-15 parts of sucralfate, 6-10 parts of tetracycline, 1-4 parts of vitamin B2, 1-4 parts of vitamin B6, 3-7 parts of vitamin C and 8-12 parts of metronidazole. The western medicine has the advantages of taking effects quickly, being good in treatment effect, having no toxic or side effects and having an excellent effect on gastric ulcer, duodenal ulcer and other diseases.

The invention aims at providing a helicobacter pylori resistant recombined VacA specificity yolk antibody with convenient available material, simplicity, economical efficiency and high stability. Sucralfate with volume percent of between 30 and 50 percent is added to the antibody to serve as a protectant, thereby improving the stability of the specificity yolk antibody against acid and pepsin, strengthening the anti-freeze thawing capacity, and maintaining the activity of the yolk antibody at room temperature. In addition, the self protective function of the sucralfate on the gastric mucosa can also be brought into play, and the sucralfate can also be used for other specificity yolk antibodies. Regarding the preparation, the material of the antibody is conveniently available, simple and economical. Two kinds of liquids can be simply mixed according to the proportion for direct taking. The specificity yolk antibody can be used for treating helicobacter pylori infection.

The invention discloses a western medicine composition for treatment of gout. The western medicine composition is prepared from, by weight in per pill, 0.2-0.5 g of sucralfate, 0.01-0.2 g of NaHCO3, 0.01-0.1 g of MgO, 0.1-0.3 g of benzbromarone, 0.2-1.5 g of analginum, 0.1-2.0 g of ketoprofen, 0.05-0.1 g of prednisone acetate, 0.05-0.2 g of eugenol and 0.05-0.1 g of naproxen. The western medicinecomposition has reasonable medicine combination and raw material coordination, can effectively treat the gout, is quick to work and is short in treatment course, and satisfies use demands at present.

The invention relates to a pharmaceutical composition formula for treating cervicitis and use of the composition formula. The composition formula contains the following effective active components: silicon dioxide nanoparticles, sucralfate and sanguis draconis polyphenol. The silicon dioxide nanoparticles, sucralfate and the sanguis draconis polyphenol are combined and are used as pharmaceutical active components, and the cervicitis is treated through local medication, so that a synergistic interaction is achieved, the curing rate of the cervicitis is high, and the cervicitis is unlikely to relapse.

The invention discloses sucralfate-colloidal bismuth pectin compound pharmaceutical tablets and a preparation method thereof. The sucralfate-colloidal bismuth pectin compound pharmaceutical tablets are prepared from, by weight, 20-60 parts of colloidal bismuth pectin (in bismuth), 10-20 parts of sucralfate (in aluminum), 30-40 parts of a belladonna extract, 20-40 parts of a milkvetch root extract, 20-40 parts of a langehead atractylodes rhizome extract, 20-40 parts of a radix saposhnikoviae extract, 50-80 parts of a radix isatidis extract, 25-30 parts of a coating agent, 3-5 parts of a disintegrating agent, 15-30 parts of a bonding agent, 2-3 parts of an excipient and 0.1-0.2 part of a corrective agent. According to the sucralfate colloidal bismuth pectin compound pharmaceutical tablets, by cooperatively using colloidal bismuth pectin and sucralfate, protection on the gastric mucosa is enhanced, and the pharmacological efficacy is improved; the traditional Chinese medicine extracts serve as an antibacterial and antiviral agent and can achieve the immunity regulating effect, enhance the immunity of the organism and decrease the disease relapse rate.

The invention discloses a compound preparation used for treating radiation bone injuries and a preparing method thereof.The compound preparation comprises calcium gluconate, monofluorophosphate glutamine, rocaltrol, nafcillin, oxacillinum natricum, durabolin, glutathione, calcitonin, icariin, vitamin AD, stanozolol, corticosteroid, sucralfate, dexamethasone and lipopolysaccharide.The compound preparation has the effects of resisting radiation, enhancing immunity and promoting bone cell metabolism, can effectively prevent complications such as radiation osteoporosis, radiation marrow, radiation fracture, osteoradionecrosis and radiation dysostosis, the formula of the compound preparation is novel and unique, the curative effect is good, cost is low, the side effect is small, and the compound preparation is widely suitable for the radiation bone injuries.

The invention belongs to the technical field of pharmaceutical engineering and specifically relates to a gel forming method for sucralfate gel having a particle size of 100-500 nm. The gel forming method for sucralfate gel having the particle size of 100-500 nm comprises the following steps: burdening, dissolving, gel forming and performing centrifugal washing. The sucralfate gel having the particle size of 100-500 nm is prepared according to a liquid phase granulating technology, and compared with common medicinal sucralfate suspension, the prepared sucralfate gel has the advantage that the mean particle size is reduced by 10-20 times; moreover, after entering gastric mucosa, the prepared sucralfate gel has strong adhesive power and long adhesion time and can be adhered to the ulcer surface, and further damage of the gastric mucosa is avoided.

The invention discloses a sucrose sulfate copper and silver compound. The structural formula (I) of the sucrose sulfate copper and silver compound is as shown in the description, wherein R represents 1/2Cu, Ag or H; the number of 1/2Cu or Ag in the sucrose sulfate copper and silver compound is greater than 1. The invention also relates to a preparation method of the compound, a pharmaceutical composition taking the compound as an active component and application of the compound and the pharmaceutical composition in preparing medicines for treating burn wounds and other traumatic infections. The compound has efficient, broad-spectrum antibacterial activity. The pharmaceutical composition of the compound has efficient activity of resisting bacteria, diminishing inflammation and promoting healing of burn wounds.

A compound medicine for treating pyrosis, gastritis, indigestion, gastrointestinal diseases, etc is proportionally prepared from ranitidine hydrochloride and sucralfate.

The present invention discloses a compound hericium dry suspension preparation. It is made up by using 600 g of hericium sporophore, 100 g of sucralfate, 50 g of magnesium trisilicate, 40 g of bismuth subnitrate, 5-15 g of polyvinylpyrrole, 50-160 g of lactose, 120-200 g of hydroxypropyl methyl cellulose, 2-6 g of Tween-80, 10-50 g of aromadenadrin powder and 3-15 g of sodium glutamate through the processes of pulverizing, granulating and filling. It has good therapeutic effect for curing ulcer of digestive tract.

The invention relates to a pharmaceutical composition for treating radiation proctitis. The pharmaceutical composition for treating the radiation proctitis consists of the following components: sucralfate, lidocaine, dexamethasone, gentamicin and a recombinant human epidermal growth factor. The invention also provides application of the pharmaceutical composition in preparing a solution preparation for retention enema. The invention provides a pharmaceutical composition, which is low in toxic and side effects, concrete in curative effect, rapid to take effect, cheap and convenient, for treating patients with the radiation proctitis; and the pharmaceutical composition is capable of improving the life quality of the patients and guaranteeing the smooth implementation of the radiotherapy.

The invention discloses helicobacter pylori eliminating oral liquid and a preparation method thereof. The helicobacter pylori eliminating oral liquid comprises egg yolk antibody and sucralfate solution, the egg yolk antibody and sucralfate solution are mixed in equal volume, and a final mass concentration of sucralfate is 10%-30%. The helicobacter pylori eliminating oral liquid and the preparation method thereof have advantages that excellent Hp infection treatment effects are achieved, and the problem that existing helicobacter pylori resisting specific IgY directly used for Hp infection treatment is not remarkably effective is solved.

The invention relates to a Chinese-Western compound preparation for treating stomach diseases and a preparation method thereof. The Chinese-Western compound preparation comprises the following raw materials in parts by weight: Codonopsis 10-15 parts, chicken gold 10-15 parts, amomum 15-20 parts, Atractylodes macrocephala 15 parts ‑20 parts, cardamom 12‑16 parts, Malan 12‑16 parts, Rehmannia glutinosa 12‑16 parts, amoxicillin 2‑5 parts, sucralfate 2‑5 parts. The present invention selects Codonopsis pilosula, chicken gold, amomum, Atractylodes macrocephala, cardamom, Malan, rehmannia glutinosa, amoxicillin and sucralfate to combine, and overcomes the problems of slow curative effect and low curative effect of pure Chinese medicine ingredients, large side effects of pure western medicine ingredients, and easy dependence defect. The combination of these medicines makes the efficacy of each medicine produce a synergistic effect, so that the recurrence of gastritis and duodenal inflammation can be effectively treated.

The invention discloses a pharmaceutical composition for treatment of schizophrenia and a preparation method and an application thereof. The pharmaceutical composition consists of the following raw materials in parts by weight: 1-5 parts of sucralfate, 7-15 parts of diclofenac sodium, 3-7 parts of aminomethylbenzoic acid, 11-19 parts of betulinic acid, and 14-22 parts of alpinetin. The preparation method comprises the steps: mixing and grinding sucralfate, aminomethylbenzoic acid and betulinic acid, adding a diclofenac sodium solution, carrying out stirring treatment for 38-40 min at a temperature of 45 DEG C, and carrying out ultrasonic treatment for 18 min at a temperature of 58 DEG C with the ultrasonic power of 800 W; then adding alpinetin, and carrying out microwave treatment for 5 min with the microwave power of 1000 W; and stirring to dry at the temperature of 67 DEG C, and granulating. The pharmaceutical composition has the advantages of good curative effect and relatively stability during schizophrenia treatment, small use amount, no toxic or side effect, stable long-term curative effect and enhanced immune function. The preparation method has the advantages of simple and easily obtained raw materials, simple preparation process, easy operation and low production cost, and is suitable for large-scale popularization.